NCT01323036

Brief Summary

The main purpose of the study is to evaluate the absorption of omega-3 fatty acids into the blood following consumption of krill oil compared with fish oil and placebo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at P25-P50 for not_applicable healthy-volunteers

Timeline
Completed

Started May 2011

Typical duration for not_applicable healthy-volunteers

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 25, 2011

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2011

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2012

Completed
Last Updated

November 22, 2012

Status Verified

November 1, 2012

Enrollment Period

7 months

First QC Date

March 23, 2011

Last Update Submit

November 21, 2012

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (1)

  • Bioavailability

    1 month

Study Arms (2)

Krill Oil

EXPERIMENTAL
Dietary Supplement: Krill oil

Fish Oil

EXPERIMENTAL
Dietary Supplement: Fish Oil

Interventions

Krill oilDIETARY_SUPPLEMENT

Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg

Krill Oil
Fish OilDIETARY_SUPPLEMENT

Fish oil: Total omega-3 fatty acids: 560-660 mg

Fish Oil

Eligibility Criteria

Age18 Years - 49 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • healthy men and premenopausal not pregnant or nursing women between 18 and 49 years old.

You may not qualify if:

  • smokers
  • rheumatoid arthritis
  • chronic illness
  • cardiovascular problems
  • dyslipidemia
  • liver and kidney disease
  • diabetes
  • endocrine or metabolic disease
  • inflammatory bowel disease
  • pancreatitis
  • gallbladder or biliary disease
  • neurological/psychological disease
  • bleeding disorders
  • experienced platelet abnormalities
  • gastrointestinal disorders that could interfere with fat absorption
  • +14 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Richardson Centre for Functional Foods and Nutraceuticals

Winnipeg, Manitoba, R3T 2N2, Canada

Location

Related Publications (2)

  • Ramprasath VR, Eyal I, Zchut S, Shafat I, Jones PJ. Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil. Lipids Health Dis. 2015 Nov 4;14:142. doi: 10.1186/s12944-015-0142-y.

    PMID: 26537218DERIVED

  • Ramprasath VR, Eyal I, Zchut S, Jones PJ. Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis. 2013 Dec 5;12:178. doi: 10.1186/1476-511X-12-178.

    PMID: 24304605DERIVED

MeSH Terms

Interventions

Fish Oils

Intervention Hierarchy (Ancestors)

OilsLipids

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of RCFFN

Study Record Dates

First Submitted

March 23, 2011

First Posted

March 25, 2011

Study Start

May 1, 2011

Primary Completion

December 1, 2011

Study Completion

November 1, 2012

Last Updated

November 22, 2012

Record last verified: 2012-11

Locations

CA(1)